Please ensure Javascript is enabled for purposes of website accessibility

Analysis: Major Pharmaceuticals' January Drug Price Hikes Were Smallest in at Least 6 Years

By Eric Volkman – Feb 5, 2020 at 5:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Analysts at investment bank Raymond James theorize that the trend will continue.

When major drugmakers delivered their customary January price hikes last month, they increased the list prices of their products by an average of 5%, according to an analysis by Raymond James. The investment bank, utilizing data from IQVIA and Wolters Kluwers, reports that this was the smallest price increase since at least 2014.

That comports with the industry's trend. In 2014, its average annual January price hike was 12%; since then, the rate has steadily fallen.

"Given the transparency the public and the government is continually seeking from the industry, combined with administration initiatives to slow the rate of list price increase levels, WAC list price increases should continue to trend toward the low to mid-single digits with longer-term potential to reach levels consistent with changes in overall inflation metrics," wrote Elliot Wilbur, the report's author. 

Pills spilling out onto US currency.

Image source: Getty Images

That said, the total number of drugs that pharmaceutical companies boosted the prices of was relatively high. According to Raymond James, last month, drugmakers hiked the costs of 2,227 medications. While that's not the highest number since 2014, it was above last year's 2,103, and significantly higher than the 2014 tally of 1,579.

The company with the highest average annual January price increase for 2020 was a generics producer -- Teva Pharmaceuticals (TEVA 3.20%). Wilbur found that Teva lifted its prices by an average of more than 6% on 36 drugs. 

On the low side of the spectrum was brand-name specialist AstraZeneca (AZN -0.13%), which boosted prices by an average of just 2.8% on a total of 31 drugs.

In terms of the company raising prices on the largest number of medications, this year's crown went to sprawling pharmaceutical giant Pfizer (PFE -0.91%) with 226. Pfizer's average annual increase was slightly over 5%.

Teva, AstraZeneca, and Pfizer -- all key pharmaceutical stocks -- traded slightly higher Wednesday. 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Pfizer Inc. Stock Quote
Pfizer Inc.
PFE
$43.76 (-0.91%) $0.40
AstraZeneca PLC Stock Quote
AstraZeneca PLC
AZN
$54.84 (-0.13%) $0.07
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$8.07 (3.20%) $0.25
Raymond James Financial, Inc. Stock Quote
Raymond James Financial, Inc.
RJF
$98.82 (0.90%) $0.88

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.